Get the Stockscreener App
0.5849
6.60%
0.0362
Longeveron Inc stock is traded at $0.5849, with a volume of 112.31K.
It is up +6.60% in the last 24 hours and up +8.11% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.5487
Open:
$0.5525
24h Volume:
112.31K
Relative Volume:
0.31
Market Cap:
$12.48M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.0874
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
+5.96%
1M Performance:
+8.11%
6M Performance:
-66.39%
1Y Performance:
-65.59%
1-Day Range:
$0.5525
$0.5949
1-Week Range:
$0.5256
$0.5949
52-Week Range:
$0.492
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5849 | 11.71M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Aug Big Picture: Is Longeveron Inc exposed to political riskJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
Revenue Check: What is Longeveron Incs revenue forecastQuarterly Trade Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Buyback Watch: What is the implied volatility of Telefnica Brasil SA Depositary ReceiptJuly 2025 Levels & Real-Time Price Movement Reports - baoquankhu1.vn
Portfolio Recap: Can Longeveron Inc continue delivering strong returnsQuarterly Portfolio Review & Comprehensive Market Scan Insights - baoquankhu1.vn
Surprises Report: Is Longeveron Inc stock a defensive play in 2025Quarterly Market Review & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Options Flow: Is Longeveron Inc stock a top momentum play2025 Technical Overview & Free Real-Time Market Sentiment Alerts - Bộ Nội Vụ
Can Longeveron Inc. stock attract ESG capital inflowsJuly 2025 Technicals & Consistent Profit Trade Alerts - Улправда
Is Longeveron Inc. stock positioned for long term growthEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Why Longeveron Inc. stock is considered a top pickJuly 2025 Volume & Consistent Return Strategy Ideas - ulpravda.ru
Will Longeveron Inc. stock continue upward momentumQuarterly Trade Review & Technical Pattern Alert System - Улправда
Is Longeveron Inc. stock a top momentum play2025 Market Overview & Long-Term Investment Growth Plans - Улправда
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Longeveron Inc.Class A Common stock (NQ: LGVN - FinancialContent
Longeveron Shares Jump as FDA Clears Phase 2 Trial for Pediatric Heart Therapy - MSN
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - marketscreener.com
Alzheimer’s ‘moonshot’ network taps Longeveron to join 2026 founder summit - Stock Titan
Longeveron (NASDAQ:LGVN) Stock Price Down 3.2% – What’s Next? - Defense World
Will Longeveron Inc. stock attract more institutional investors2025 Market WrapUp & Weekly High Conviction Trade Ideas - Улправда
Is Longeveron Stock Built to Withstand More Downside? - Trefis
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
What drives Longeveron Inc stock priceDouble Top/Bottom Patterns & Trusted Financial Advisors at No Cost - earlytimes.in
Longeveron Earnings Notes - Trefis
Is Longeveron Inc. stock a good choice for value investorsNew Guidance & Verified Stock Trade Ideas - Улправда
What risks investors should watch in Longeveron Inc. stockPortfolio Return Summary & Comprehensive Market Scan Reports - DonanımHaber
Why Longeveron Inc. stock remains on watchlists2025 Valuation Update & Technical Confirmation Trade Alerts - DonanımHaber
Is Longeveron Inc. stock a buy in volatile marketsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
What technical signals suggest for Longeveron Inc. stockEarnings Summary Report & Fast Moving Stock Trade Plans - Улправда
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction - Investing.com Canada
Longeveron granted U.S. patent for method of treating female sexual dysfunction - marketscreener.com
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction By Investing.com - Investing.com South Africa
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy - The Manila Times
Block Trades: What risks investors should watch in Longeveron Inc stockRate Cut & Free High Return Stock Watch Alerts - moha.gov.vn
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Prepare Yourself for Liftoff: Longeveron Inc (LGVN) - Setenews
With Longeveron Stock Sliding, Have You Assessed The Risk? - Trefis
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - The Manila Times
Longeveron (NASDAQ: LGVN) CSO, CMO to Join CVCT Forum Panels on Cell Therapy Trials - Stock Titan
Can Longeveron Inc. stock continue upward trendWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Longeveron (LGVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Longeveron receives Canadian patent for stem cell therapy By Investing.com - Investing.com Nigeria
Perhaps timely catching Longeveron Inc (LGVN) would be a good idea - Setenews
Longeveron receives Canadian patent for stem cell therapy - Investing.com
Longeveron granted Canadian patent for method of using stem cells to treat non-ischemic dilated cardiomyopathy - MarketScreener
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - The Manila Times
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial By Investing.com - Investing.com South Africa
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):